ACE2-Targeting Monoclonal Antibody As A "Pan" Coronavirus Blocker In Vitro and In A Mouse Model

0 views • Sep 30, 2021
0
Save
Cite
Share

Author(s)

Author Name

Uploader

Yuning Chen

Published 2 Projects

Immunology Genetics

Yanan Zhang

Published 1 Project

Immunology

Renhong Yan

Published 1 Project

Immunology

Guifeng Wang

Published 1 Project

Immunology

Yuanyuan Zhang

Published 1 Project

Immunology

Zherui Zhang

Published 1 Project

Immunology

Yaning Li

Published 1 Project

Immunology

Wendi Chu

Published 1 Project

Immunology

Yili Chen

Published 1 Project

Immunology

Ganjun Chen

Published 1 Project

Immunology

Qi Wang

Published 1 Project

Immunology

Qiang Zhou

Published 1 Project

Immunology

Bo Zhang

Published 1 Project

Immunology

Chunhe Wang

Published 1 Project

Immunology

Add New Author

Coronaviruses have caused three major outbreaks of infectious disease since the beginning of 21st century. Broad-spectrum strategies that can be utilized in both current and future coronavirus outbreaks and mutation-tolerant are sought after. Here we report a monoclonal antibody 3E8 targeting human angiotensin-converting enzyme 2 (ACE2) neutralized pseudo-typed coronaviruse SARS-CoV-2, SARS-CoV-2-D614G, SARS-CoV and HCoV-NL63, without affecting physiological activities of ACE2 or causing toxicity in mouse model. 3E8 also blocked live SARS-CoV-2 infection in vitro and in a mouse model of COVID-19. Cryo-EM studies revealed the binding site of 3E8 on ACE2 and identified Histone 34 of ACE2 as a critical site of anti-viral epitope. Overall, our work has provided a potential pan coronavirus management strategy and disclosed a pan anti-coronavirus epitope on human ACE2 for the first time. ### Competing Interest Statement Yi-Li Chen, Ganjun Chen and Chunhe Wang are employed by Dartsbio Pharmaceuticals

Immunology
Immunology 27 Projects